Retrophin Inc. (RTRX) CEO Sells $173,184.00 in Stock
Retrophin Inc. (NASDAQ:RTRX) CEO Steve Aselage sold 8,200 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $21.12, for a total transaction of $173,184.00. Following the sale, the chief executive officer now directly owns 248,756 shares of the company’s stock, valued at approximately $5,253,726.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Retrophin Inc. (NASDAQ:RTRX) traded up 1.75% during trading on Wednesday, hitting $21.49. 465,580 shares of the stock traded hands. The stock’s market cap is $810.86 million. Retrophin Inc. has a 12 month low of $11.60 and a 12 month high of $24.57. The company has a 50-day moving average price of $20.62 and a 200-day moving average price of $18.95.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.38 by $0.47. Retrophin had a negative net margin of 32.96% and a negative return on equity of 1.33%. The firm had revenue of $33.95 million for the quarter, compared to analysts’ expectations of $34.84 million. During the same quarter last year, the business earned ($0.05) earnings per share. The business’s revenue was up 21.2% compared to the same quarter last year. Equities research analysts expect that Retrophin Inc. will post ($1.32) EPS for the current year.
A number of institutional investors have recently made changes to their positions in RTRX. BlackRock Fund Advisors boosted its position in shares of Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock worth $17,799,000 after buying an additional 22,903 shares during the period. GW&K Investment Management LLC boosted its position in shares of Retrophin by 12.2% in the second quarter. GW&K Investment Management LLC now owns 95,987 shares of the biopharmaceutical company’s stock worth $1,710,000 after buying an additional 10,465 shares during the period. Bank of Montreal Can purchased a new position in shares of Retrophin during the second quarter worth approximately $368,000. Boston Advisors LLC boosted its position in shares of Retrophin by 23.8% in the second quarter. Boston Advisors LLC now owns 26,945 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 5,185 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Retrophin by 2.5% in the second quarter. California State Teachers Retirement System now owns 75,938 shares of the biopharmaceutical company’s stock worth $1,352,000 after buying an additional 1,869 shares during the period.
Several equities analysts recently commented on RTRX shares. Zacks Investment Research raised shares of Retrophin from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, October 12th. JMP Securities reissued an “outperform” rating and issued a $28.00 price objective on shares of Retrophin in a research note on Friday, September 9th. BMO Capital Markets reissued an “outperform” rating and issued a $28.00 price objective (up previously from $25.00) on shares of Retrophin in a research note on Monday, August 8th. Leerink Swann increased their price objective on shares of Retrophin from $27.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, September 7th. Finally, TheStreet downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $29.60.
COPYRIGHT VIOLATION WARNING: This piece of content was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/23/retrophin-inc-rtrx-ceo-sells-173184-00-in-stock.html.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.